Rencofilstat
Phase 2Small molecule
Rencofilstat is one of 43 small molecule programs targeting Fibrosis. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
113 competitors in Fibrosis
#DrugCompanyPhaseTrials
1Gleevec
NovartisPhase 3
PEG-Intron
Merck & Co.Phase 3
Atacand
AstraZenecaPhase 3
Esbriet
LLegacy Health System
Phase 3
Ofev
Boehringer IngelheimPhase 3
Ocaliva
IIntercept Pharmaceuticals
Phase 3
Myfortic
NovartisPhase 3
Ozempic
Novo NordiskPhase 2
Trental
VValidus Pharmaceuticals
Phase 2
Pegozafermin
89bioPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rencofilstat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHepion Pharmaceuticals, Inc.